IDH1 and acute myeloid leukemia: Ivosidenib was approved by the FDA for patients with relapsed or refractory IDH1-mutated AML in 2018, and also as a front-line therapy for newly diagnosed elderly patients 75 years or older or who are ineligible to receive intensive chemotherapy in 2019 [132].